Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The therapeutic significance of concomitant antitumor immunity

II. Passive transfer of concomitant immunity with Ly-1+2 T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression

  • 12 Accesses

  • 21 Citations

Summary

Intravenous injection of 50 μg bacterial endotoxin can cause complete regression of an established SA1 sarcoma, but not if the tumor ir growing in mice that are incapable of generating concomitant immunity because they have been made T cell-deficient by thymectomy and γ-radiation (TXB mice). It also was shown that endotoxin fails to cause complete regression of a tumor that is either too large or too small. Only when administered on day 9 of tumor growth, at the time of peak concomitant immunity, did endotoxin cause the tumor to undergo complete regression. Direct evidence that the antitumor effect of endotoxin is dependent on concomitant immunity consisted in the demonstration that an SA1 sarcoma growing in TXB recipients can be primed for endotoxin-induced regression by IV infusion of splenic T cells from concomitantly immune donors bearing an endotoxin-susceptible 9-day tumor. Surprisingly, the donor T cells that primed the recipient tumor for endotoxin-induced regression were of the Ly-1+2 phenotype, as evidenced by their susceptibility to treatment with anti-Ly-1 antibody and complement, and their complete resistance to treatment with anti-Ly-2 antibody and complement. They were different, therefore, from the T cells that cause the regression of smaller tumors in γ-irradiated recipients without the aid of endotoxin. It is suggested that the antitumor function of endotoxin depends on its ability to cause intratumor macrophages to acquire and express tumoricidal function, but only after the macrophages have been activated by Ly-1+2 tumor-sensitized T cells.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Alexander P, Evans R (1971) Endotoxin and double-stranded RNA render macrophages cytotoxic. Nature New Biol 232:76

  2. 2.

    Berendt MJ, North RJ, Kirstein DP (1978a) Immunological basis of endotoxin-induced tumor regression. Requirement for T cell-mediated immunity. J Exp Med 148:1550

  3. 3.

    Berendt MJ, North RJ, Kirstein DP (1978b) Immunological basis of endotoxin-induced tumor regression. Requirements for a preexisting state of concomitant antitumor immunity. J Exp Med 148:1560

  4. 4.

    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis in tumors. Proc Natl Acad Sci USA 72:3666

  5. 5.

    Evans R (1972) Macrophages in syngeneic animal tumors. Transplantation 14:468

  6. 6.

    Kelso A, MacDonald HR (1982) Precursor frequency analysis of lymphokine-secreting alloreactive T lymphocytes. Dissociation of subsets producing interleukin 2, macrophage-activating factor, and granulocyte-macrophage colony-stimulating factor on the basis of Lyt-2 phenotype. J Exp Med 156:1366

  7. 7.

    Meltzer MS (1981) Tumor cytotoxicity by lymphokine-activated marophages: development of macrophage tumoricidal activity requires a sequence of reactions. In: Lymphokines. Academic Press, New York p 319

  8. 8.

    Mills CD, North RJ, Dye ES (1981) Mechanisms of antitumor action of Corynebacterium parvum. Potentiated cytolytic T cell response and its tumor-induced suppression. J Exp Med 154:621

  9. 9.

    Nauts HC, Fowler GA, Bogatko FH (1953) A view of the influence of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand 145:5

  10. 10.

    North RJ (1984) The therapeutic significance of concomitant antitumor immunity. I. Ly-12+ T cells from mice with a progressive tumor can cause the regression of an established tumor in γ-irradiated recipients. Cancer Immunol Immunother 18:69

  11. 11.

    North RJ, Day ES, Mills CD, Chandler JP (1983) Modulation of antitumor immunity — immunobiologic approaches. Springer Semin Immunopathol 5:193

  12. 12.

    Russell SW, Doe WF, MCIntosh AT (1977) Functional characterization of a stable noncytolytic stage of macrophage activation in tumors. J Exp Med 146:1511

  13. 13.

    Shear MJ (1943) Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhagic-producing bacterial polysaccharide. J Natl Cancer Inst 4:461

  14. 14.

    Tuttle RL, Knick VC, Stopford CR, Wolberg G (1983) In vivo and in vitro antitumor activity expressed by cells of concomitant immune mice. Cancer Res 43:2600

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

North, R.J. The therapeutic significance of concomitant antitumor immunity. Cancer Immunol Immunother 18, 75–79 (1984). https://doi.org/10.1007/BF00205737

Download citation

Keywords

  • Tumor Growth
  • Cancer Research
  • Sarcoma
  • Direct Evidence
  • Intravenous Injection